QRxPharma has executed its License and Option Agreement (LOA) with Actavis, finalizing the terms and conditions to commercialize MoxDuo IR in the U.S. for acute pain. In December 2011, the companies signed a letter of intent secured by a $6 million non-refundable upfront signing fee to QRxPharma.

“Actavis is proving to be an exceptional partner. The strategic synergies between our companies and our collaboration at the joint steering committee level are critical success factors going forward,” said Dr. John Holaday, managing director and chief executive officer, QRxPharma. “With the LOA now complete, we are focusing our ongoing energies towards supporting Actavis as we approach our PDUFA date and prepare for the anticipated launch of our first product, MoxDuo IR, in the third quarter.”

Doug Boothe, Actavis’ chief executive officer for the U.S., said, “Our launch plans for MoxDuo IR are on track and we remain convinced MoxDuo IR is very well suited to the experience and expertise of our marketing and sales teams. We are very optimistic about the opportunity for MoxDuo IR to successfully penetrate the $2.5 billion acute pain market in the U.S.”

Additionally, Actavis has an option to negotiate for U.S. marketing and sales rights for MoxDuo CR, a controlled release Dual-Opioid for chronic pain, as well as MoxDuo IV, a hospital-based intravenous formulation.